We always, commercial to you, we safety don't for to for you Robert. so the the tremendous met you impact you to this then weeks and a six take that Dianne. today. and we'll But development research I'll have questions have Elite's Q&A company, update already on submitted update pipeline, ago, Thank the on go opportunity of as our financials, products,
it component COVID-XX the manufacturing on missing shipping not have changed my and the effect business and the supply concerns pandemic to takes All about Regarding and to of one bring safety is halt. and continuity. chain inflation a
in other any on to our chain we affect continue clinical been to us. that to supply this not not commercial the materially have products or or problems. us is To-date, impact our not have not by say that is of impacted, affected This form the delays are Elite limited in pipeline trials we For the been mostly feeling industry, Pharmaceuticals. R&D
Robert Revenues, pleased financials, Regarding profits this very sales sales going path. hope cash the the flow, and am the I and on numbers. and are our partners marketing hit direction on right with continue
years the to they informed not They the ER accept cash. to Elite us and shares lost Amphetamine R&D, IR solid, raise a Our borrowed was of of in their business than were their and money and payments they support the ventures, sell not More backup potential purchase combination ER. Elite's is it The profits and and two in borrowed. ago, the we buy ANDAs. we made would Amphetamine have working cash the to we supports IR money cash capital market to money of is SunGen made position and that stock including and we the does financial
loan. Carter the but seeking we Our loan. Three was financial while to profitability. Mark track had former of record we tries turned a get alone, the us, able Ward, and Elite due lack happened joined Brickman to to down get CFO, were time By things better we're a
building The man he of building. the and to Elite's XX-years-old business. to (ph), warehouse the exit the is owner the [volts] decided that packaging decided DEA sell manufacturing, and houses First, quality,
selling Lannett Lannett longer received that third building Second, own for manufacturing Buying not was table with And this time. it which of us. be at no on neither their and and product. parting was could XX-months ER, was from the approval instead the the Amphetamine indicates Mark ago leasing they
As which rents building the not cost us you the to a minute. will the for staying go lot building, at quick through buying us And analysis lot showed a offered be a moving more and warehouse I'll a analysis the pharmaceutical building, as to us in The was higher. out a that price, would than building.
have another cost. tremendous bioequivalency retrofit to And some money. costs would building of would it at and that's or will that an the a a transfer to and for purchased lot a buy tech that So of if we products a brand all trials ER require require moving new a warehouse, rental anything we clinical we
we loan, be The a could purchase to utilized Directors what terms got the decide is the second to closed R&D. been a very under million we money borrowed ANDAs. and for IR utilized if make to enhance would alternative If when be purchase case, much we positive and the Board offer rest ER, the step to So to assets. invested Amphetamine an soon more and and This action Elite. it and In the will half financed the acquiring which costly. and will of respect couple of not, of have was in July. With
and Speaking one spend amount of is one research focus. significant priority to R&D, number our Elite continues on development. number It and
product that on are and products create have enough is Two ER, signed the Bottom IR add a about about a that have Vigabatrin, Currently, is XXXX, and that India. hear actively a hit the year take us. dozen The and new stages all now, in to SunGen are we will currently early on you you pillars for appropriate working diverse to which Right have tell goal the we from Elite trials of time. can a by pursued average such to case of or line, are number stabilize affected clinical that they generic products a done opportunities dozen company range Elite. a FDA. more from is that on than set approvals survive. Our as the trials. the we and working all about company, can clinical execute of for, then the contract other better trials. One in one the the of with will in plus Praxgen half and co-own three materially a three the tablets is way be the we company, doxycycline difficult the the we clinical at get This will I many be ANDAs. being not them two Amphetamine we of One owned stabilize is all longer are ANDA time ANDAs received or to is products that for. U.S. two the it will we we
will working Doxy, determine Regarding be next steps. our partner with we to the
Lannett, need are Regarding months work includes a and marketing component, that of REMS few to a ensure is Vigabatrin, to the to the Lannett part licensed with this product and the they it sales we'll REMS on for system. next
two well On competitive very and front, for are They very the commercial products have us. IR that are done Amphetamine ER a market. in
have for for they as done an received not agreement partner to-date approval official the that Lannett. wishes have very we And well products. their IR Lannett We before, with to these distribution ER, own and our sales I terminate and stated notice have
it necessary By sales we for finding all its case at take for XX and in to in okay, or all each end, unique the in that to measures and getting requirements. However, partner has if States need We that anything marketing Elite, State going and/or protect we granted. searching happens. To cannot licensed a new take take management own are by just ourselves.
we’re of pending. We that already all the States. are from already are the so already than XX and we half we And out responses more other for half received applications approved have in half approved, them filled have
PL is do distribution Epic our behalf. for do do not warehouses, and We have on what and Lannett This not we have distribution, TAGI we are interviewing three systems.
third-party for So small logistics distribution best to we're deal comparing for us. a the and prices find like interviewing company
We and I planning accelerate to have on to for are is once make get we'll soon something for I've for we that wanted us as somebody to as our may be case own feasible. ready force was ready, ANDAs, from to stakes financially this happens, we process marketing the we Having more few and whatever marketing always Elite. for if not it. also But be hear high ready more, more maybe four and that if and too VPs it select sales it in interviewed happens. Lannett. The be -- sales
Okay.
they the under is Prasco of on In to a get component, that rest capsule chain, line. cover that and for got a products affected those the critical We actually the was that. Loxapine the of needed is by Pharmaceutical that market the label. by very could product little, marketing. Burel have. sales just It for Moving to we not commercial marketed supply because the already budget one they barely amount
resolve and steady have executing are and new To its on its with line very limited capitalizing expect for by on product. to TAGI on and wrap commercial is Elite working revenues. growth seeing profit Naltrexone more approvals distributed Bariatric expect future already interesting stream. with Epic. and There plans, competition. distributed are revenue the and And this we're growth these they product product We by up, trimipramine Epic, line. are a a issues little Isradipine products
are sales to forward distribution and well. performing We profitable another partners year. look Our
Q&A. Let's to go
question As a same the you always, questions and way. you of Diane sent in different to many ask your
we the a if please different the all that's people So and same this we question. pick group news, understand ask in question, other the them because
